| HOME >> BIOLOGY >> TECHNOLOGY |
December 31, 2006
Vermillion, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(In Thousands, Except Per Share Amounts)
(Unaudited)
Three Months Ended Year Ended
December 31, December 31,
2007 2006 2007 2006
Revenue $23 $1,216 $44 $18,215
Cost of revenue 13 506 28 9,338
Gross profit 10 710 16 8,877
Operating expenses:
Research and
development 1,916 2,693 8,213 11,474
Sales and marketing 735 1,916 2,175 12,568
General and
administrative 2,232 3,112 10,858 10,661
Total operating expenses 4,883 7,721 21,246 34,703
Gain on sale of
instrument business 1,992 6,929 1,610 6,929
Loss from operations (2,881) (82) (19,620) (18,897)
Loss on extinguishment
of debt - (1,481) - (1,481)
Interest and other
expense, net (247) (326) (1,499) (1,536)
Loss before income
taxes (3,128) (1,889) (21,119) (21,914)
Income tax benefit
(expense) (164) 38 (163) (152)
Net loss $(3,292) $(1,851) $(21,282) $(22,066)
Loss per share -
basic and diluted (1) $(0.52) $(0.49) $(4.47) $(6.05)
Shares used to
compute basic and
diluted loss per
common sha
'/>"/>
| SOURCE Vermillion, Inc. Copyright©2008 PR Newswire. All rights reserved |